Oxford Gene Technology SureSeq CLL + CNV Panel
Oxford Gene Technology has launched the SureSeq CLL + CNV Panel for cancer research. The next-generation sequencing assay has been designed in collaboration with cancer experts to detect 12 key genes and five chromosomal regions implicated in chronic lymphocytic leukemia (CLL) progression.
The panel alleviates the burden of running multiple assays and delivers a comprehensive genomic profile for each CLL sample using a single workflow. It can identify loss of heterozygosity, copy number variation with a size range of a single exon to the whole gene, loss of chromosomal arms, and whole chromosome gains in trisomy 12. It comes with complimentary data analysis software.